NTDs occur in rural populations primarily located in the poorest communities of Africa, Latin America and Asia. Consequently, there is a limited commercial market for NTD vaccines; thus, upscaling investment for these vaccines is unlikely due to the current profit driven motivation of pharmaceutical companies. Without the appropriate assurance that companies will recover their financial investments in research and development, multinational corporations have been reluctant to support vaccine development initiatives for NTDs. Additionally, developing vaccines for soil-transmitted helminths and protozoan diseases require complex research and an intricate understanding of the pathogenesis of each of these disease causing microorganisms.